Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series

Weng, Han‐Rong; Wang, T.‐S.; Tsai, Tsen‐Fang

doi:10.1111/bjd.16252

Cited by 34 publications

(33 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In real-world and case studies, approximately 60% of patients with erythrodermic PsO receiving secukinumab achieved PASI75 by week 4, suggesting that secukinumab may be a viable, rapid treatment option for this challenging population [80,81]. However, in patients who experienced failure of multiple prior therapies, the effectiveness of secukinumab was suboptimal [82]. Further research is needed to evaluate the optimal dosage and treatment frequency.…”

Section: Rare Forms Of Psomentioning

confidence: 99%

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence

Merola

Feldman

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Psoriasis (PsO) is a common, systemic, chronic, inflammatory disease characterized by key clinical symptoms, including itching, pain, and scaling. PsO is associated with a high prevalence of comorbidities, including other autoimmune diseases and malignancies. Furthermore, special populations, such as pregnant, pediatric, and elderly patients, and those with erythrodermic PsO, are challenging to treat and require tightly monitored disease and treatment management. Because certain populations have demographic or clinical characteristics that can affect the presentation of PsO and complicate treatment responses, these patient populations are largely excluded from clinical trials; therefore, most clinical evidence for the treatment of these patients is derived from case reports and series. Secukinumab, a fully human monoclonal interleukin-17A antibody, has been shown in several clinical trials to be effective and safe for the treatment of PsO; however, these studies offer only limited data on the use of secukinumab in patients with chronic illnesses or in special populations. This review explores the use of secukinumab for PsO in special populations, including pregnant women, children, elderly people, patients with erythrodermic PsO, and those with chronic illnesses, including latent tuberculosis, hepatitis B and C, HIV, multiple sclerosis, and malignancies.

show abstract

Section: Rare Forms Of Psomentioning

confidence: 99%

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence

Merola

Feldman

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…Secukinumab is a human IgG monoclonal antibody that selectively binds to the interleukin 17A (IL‐17A) inhibiting the releasing of proinflammatory cytokines and chemokines, and its efficacy in the treatment of EP has been reported in several cases 26,29,30 . A recent pilot study evaluated the use of secukinumab in 13 EP patients: 10 of them were responders at week 52 and achieved PASI 90 or PASI 100 without recurrence or adverse reactions 34 .…”

Section: Discussionmentioning

confidence: 99%

Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab

Pizzatti

Mugheddu

Sanna

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Erythrodermic psoriasis is a severe, life‐threatening condition with additional complications, when occurring in hemodialyzed patients, as the majority of treatments are contraindicated. A 44‐years‐old man, of Philippine origins, with a 15‐years‐history of psoriasis treated with cyclosporine developed progressive hypertension and renal insufficiency. Despite drug dismission, renal function worsen to end‐stage, and hemodialysis was necessary three times a week. Phototherapy was not able to control the skin condition, progressing to erythroderma, and after nephrology consultation, the patient consent to the off‐label secukinumab treatment, at the standard regimen (300 mg subcutaneously once weekly at weeks 0‐4 followed by 300 mg every 4 weeks). Seven days after the first injection, a rapid improvement was noted, with the psoriasis area severity index (PASI) score passing from 31.5 to 17.6. At the 52‐week‐follow‐up visit, the patient was completely clarified, without any side effects. The case supports secukinumab effectiveness and safety in difficult patients, including erythrodermic psoriasis with end‐stage renal failure, as drug plasma levels seem not to be affected by hemodialysis. Results are rapidly achieved, and long term maintained, with the additional advantage of a very comfortable monthly administration.

show abstract

“…The PASI 75 and PASI 90 response rates were lower in our series than in the pivotal phase III study . The treatment effect was also lower than our previous EP case series treated with secukinumab …”

Section: Patient Demographics: Nine Cases Of Erythrodermic Psoriasismentioning

confidence: 99%

Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series

Tsai

2019

Br J Dermatol

Self Cite

View full text Add to dashboard Cite

3 Lacruz RS, Feske S. Diseases caused by mutations in ORAI1 and STIM1. Ann N Y Acad Sci 2015; 1356:45-79. 4 Lian J, Cuk M, Kahlfuss S et al. ORAI1 mutations abolishing store-operated Ca 2+ entry cause anhidrotic ectodermal dysplasia with immunodeficiency. J Allergy Clin Immunol 2018; 142:1297-310. 5 Davis FM, Janoshazi A, Janardhan KS et al. Essential role of Orai1 store-operated calcium channels in lactation. Proc Natl Acad Sci USA 2015; 112:5827-32. 6 Endo Y, Noguchi S, Hara Y et al. Dominant mutations in ORAI1 cause tubular aggregate myopathy with hypocalcemia via constitutive activation of store-operated Ca 2+ channels. Hum Mol Genet 2015; 24:637-48. 7 Vandenberghe M, Raphael M, Lehen'kyi V et al. ORAI1 calcium channel orchestrates skin homeostasis. Proc Natl Acad Sci USA 2013; 110: E4839-48. 8 Numaga-Tomita T, Putney JW. Role of STIM1-and Orai1-mediated Ca 2+ entry in Ca 2+ -induced epidermal keratinocyte differentiation.

show abstract

Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series

Cited by 34 publications

References 8 publications

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence

Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab

Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series

Contact Info

Product

Resources

About